Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, wh… Read more
Market Cap & Net Worth: Hikal Limited (HIKAL)
Hikal Limited (NSE:HIKAL) has a market capitalization of $256.63 Million (₹22.22 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #19199 globally and #939 in its home market, demonstrating a -3.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hikal Limited's stock price ₹180.25 by its total outstanding shares 123300750 (123.30 Million).
Hikal Limited Market Cap History: 2015 to 2026
Hikal Limited's market capitalization history from 2015 to 2026. Data shows growth from $149.98 Million to $256.63 Million (7.25% CAGR).
Index Memberships
Hikal Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$69.23 Billion | 0.11% | #196 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.01% | #641 of 750 |
Weight: Hikal Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hikal Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hikal Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Hikal Limited's market cap is 0.02 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.36x
Hikal Limited's market cap is 0.36 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $193.79 Million | $9.08 Billion | $412.01 Million | 0.02x | 0.47x |
| 2017 | $213.23 Million | $10.33 Billion | $677.16 Million | 0.02x | 0.31x |
| 2018 | $214.75 Million | $12.99 Billion | $772.27 Million | 0.02x | 0.28x |
| 2019 | $158.06 Million | $15.88 Billion | $1.03 Billion | 0.01x | 0.15x |
| 2020 | $230.35 Million | $15.05 Billion | $844.35 Million | 0.02x | 0.27x |
| 2021 | $740.93 Million | $17.07 Billion | $1.33 Billion | 0.04x | 0.56x |
| 2022 | $579.40 Million | $19.26 Billion | $1.60 Billion | 0.03x | 0.36x |
| 2023 | $431.05 Million | $20.05 Billion | $783.82 Million | 0.02x | 0.55x |
| 2024 | $555.97 Million | $17.69 Billion | $696.02 Million | 0.03x | 0.80x |
| 2025 | $322.95 Million | $18.60 Billion | $908.00 Million | 0.02x | 0.36x |
Competitor Companies of HIKAL by Market Capitalization
Companies near Hikal Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Hikal Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hikal Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Hikal Limited's market cap moved from $149.98 Million to $ 256.63 Million, with a yearly change of 7.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹256.63 Million | -20.54% |
| 2025 | ₹322.95 Million | -41.91% |
| 2024 | ₹555.97 Million | +28.98% |
| 2023 | ₹431.05 Million | -25.60% |
| 2022 | ₹579.40 Million | -21.80% |
| 2021 | ₹740.93 Million | +221.66% |
| 2020 | ₹230.35 Million | +45.73% |
| 2019 | ₹158.06 Million | -26.40% |
| 2018 | ₹214.75 Million | +0.71% |
| 2017 | ₹213.23 Million | +10.04% |
| 2016 | ₹193.79 Million | +29.21% |
| 2015 | ₹149.98 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hikal Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $256.63 Million USD |
| MoneyControl | $256.63 Million USD |
| MarketWatch | $256.63 Million USD |
| marketcap.company | $256.63 Million USD |
| Reuters | $256.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.